Results 21 to 30 of about 2,864 (172)

Predicting nitroimidazole antibiotic resistance mutations in Mycobacterium tuberculosis with protein engineering.

PLoS Pathogens, 2020
Our inability to predict which mutations could result in antibiotic resistance has made it difficult to rapidly identify the emergence of resistance, identify pre-existing resistant populations, and manage our use of antibiotics to effectively treat ...
Brendon M Lee, Liam K Harold, Deepak V Almeida, Livnat Afriat-Jurnou, Htin Lin Aung, Brian M Forde, Kiel Hards, Sacha J Pidot, F Hafna Ahmed, A Elaaf Mohamed, Matthew C Taylor, Nicholas P West, Timothy P Stinear, Chris Greening, Scott A Beatson, Eric L Nuermberger, Gregory M Cook, Colin J Jackson   +17 more
doaj   +1 more source

Scoping review: QT interval prolongation in regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis

International Journal of Mycobacteriology, 2022
Background: A regimen containing bedaquiline–delamanid is recommended in management of drug-resistant tuberculosis (DR TB) to increase a success rate.
Oki Nugraha Putra, Yulistiani Yulistiani, Soedarsono Soedarsono   +2 more
doaj   +1 more source

Culture conversion at six months in patients receiving bedaquiline- and delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis

International Journal of Infectious Diseases, 2021
Rifampicin-resistant/multidrug-resistant (RR/MDR) and extensively drug-resistant (XDR) strains of M. tuberculosis (TB) are serious public health problem in Kazakhstan.
Shynar M. Maretbayeva, Anar S. Rakisheva, Malik M. Adenov, Lyazzat T. Yeraliyeva, Yerkebulan Zh. Algozhin, Assel T. Stambekova, Elmira A. Berikova, Askar Yedilbayev, Michael L. Rich, Kwonjune J. Seung, Assiya M. Issayeva   +10 more
doaj   +1 more source

Effectiveness and cardiovascular safety of delamanid-containing regimens in adults with multidrug-resistant or extensively drug-resistant tuberculosis: A nationwide cohort study from Belarus, 2016-18

Monaldi Archives for Chest Disease, 2021
To address the sub-optimal treatment outcomes among patients with multidrug-resistant (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB), the National TB Programme in Belarus started using new drugs such as bedaquiline and delamanid in 2015-16.
Vera Auchynka, Ajay M.V. Kumar, Hennadz Hurevich, Yuliia Sereda, Varvara Solodovnikova, Dzmitry Katovich, Svetlana Setkina, Askar Yedilbayev, Aliaksandr Skrahin, Alena Skrahina   +9 more
doaj   +1 more source

Comparison of Individual Regimen Containing Bedaquiline with Delamanid and Bedaquiline without Delamanid on Efficacy and Safety in Multidrug-resistant Tuberculosis Patients: Implementation in Dr. Soetomo General Academic Hospital, Indonesia

International Journal of Mycobacteriology
Background: Bedaquiline is one of the core drugs used to treat multidrug-resistant TB (MDR-TB). Delamanid is one of the companion drugs in group C which is used to complete the treatment regimen when drugs in groups A and B can not be used.
Soedarsono Soedarsono, Ni Made Mertaniasih, Tutik Kusmiati, Ariani Permatasari, Susi Subay, Suko Hari Adiono   +5 more
doaj   +1 more source

Delamanid in the Treatment of MDR/pre-XDR TB in Arkhangelsk Region in 2019–2021

Туберкулез и болезни лёгких, 2023
The objective: to evaluate the efficacy and safety of delamanid in a short-course treatment regimen for patients with MDR/pre-XDR pulmonary tuberculosis in Arkhangelsk Region from 2019 to 2021.Subjects and Methods.
E. S. Khimova, D. V. Perkhin, O. M. Sveshnikova, S. V. Makhmaeva, V. N. Verkhovaya, P. I. Eliseev, E. I. Nikishova, A. O. Maryandyshev   +7 more
doaj   +1 more source

Use of Short Oral Regimens for Treatment of Drug Resistant Tuberculosis in a Patient with HIV Infection

Туберкулез и болезни лёгких, 2023
We present the clinical case of effective treatment of tuberculosis in a patient with disseminated pulmonary and extrapulmonary pre-extensive drug resistant tuberculosis, HIV-infection and other severe opportunistic and concomitant infections.
S. Yu. Degtyareva, T. A. Kuznetsova, V. N. Zimina   +2 more
doaj   +1 more source

DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid

Nature Communications, 2023
Mycobacterium tuberculosis is one of the global leading causes of death due to a single infectious agent. Pretomanid and delamanid are new antitubercular agents that have progressed through the drug discovery pipeline.
Katherine A. Abrahams, Sarah M. Batt, Sudagar S. Gurcha, Natacha Veerapen, Ghader Bashiri, Gurdyal S. Besra   +5 more
doaj   +1 more source

Delamanid for Multidrug-Resistant Pulmonary Tuberculosis [PDF]

New England Journal of Medicine, 2012
Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis.In this randomized, placebo-controlled, multinational clinical trial, we assigned 481 patients (nearly
Maria Tarcela, Gler, Vija, Skripconoka, Epifanio, Sanchez-Garavito, Heping, Xiao, Jose L, Cabrera-Rivero, Dante E, Vargas-Vasquez, Mengqiu, Gao, Mohamed, Awad, Seung-Kyu, Park, Tae Sun, Shim, Gee Young, Suh, Manfred, Danilovits, Hideo, Ogata, Anu, Kurve, Joon, Chang, Katsuhiro, Suzuki, Thelma, Tupasi, Won-Jung, Koh, Barbara, Seaworth, Lawrence J, Geiter, Charles D, Wells   +20 more
openaire   +2 more sources

Evaluation of the effectiveness of bedaquiline and delamanid treatment among children and adolescents with multi-drug-resistant pulmonary tuberculosis

Сучасна педіатрія: Україна, 2023
Introduction. Against the backdrop of multiple and widespread drug resistance of Mycobacterium tuberculosis (MDR-TB), there has been a significant decline in the effectiveness of treatment of tuberculosis (TB) patients in Ukraine and globally. Therefore,
M.I. Sakhelashvili, I.L. Platonova, O.I. Sakhelashvili-Bil, Z.I. Piskur   +3 more
doaj   +1 more source